Global Health Q2 FY27 Share Price & Earnings Call Analysis

Part of: Nifty Midcap 150 · NIFTY LargeMidcap 250 · Nifty MidSmallcap 400 · Nifty 500 · Nifty Total Market

₹1,427.10+2.12% today
Market cap
₹38,381 Cr
P/E
59.28
ROE
15.17%
PEG
3.04
Price to sales
7.60
Debt to equity
0.31
52W high / low
₹1,509 / ₹961
Sales growth (5Y)
24.97%
EBITDA margin
22.12%
Net profit margin
12.58%
Promoter holding
33.00%
Sales (last year)
₹5,053 Cr

Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.[1]

Guidance scorecard · Q2 FY27 call

What Global Health's management guided
and where it ranks in Healthcare Services

#10of 32 in
Healthcare Services

RevenueQ2 FY27 call

20–40%
  • Strong growth trajectory with 34% YoY increase in consolidated revenue from operations in Q2 FY27.
  • Inpatient volumes grew 30% YoY; outpatient volumes increased 38% YoY, indicating sustained demand.
  • Capacity expansion includes adding approx. 3,450 beds over next few years, nearly doubling network capacity to 7,600 beds.
  • Planned capital expenditure of over INR 6,000 crores in next 4-5 years for new hospitals, capacity expansion, and infrastructure.
  • Cluster 2 hospitals (developing units) show robust volume growth, e.g., 26% inpatient volume increase ex-Noida.
  • Growth driven by volume rather than tariff hikes; ARPP stable with nominal increases (~5% or less).
  • Expansion into new regions like Ghaziabad with planned 500-bed facility to tap emerging markets.

2 more points from Global Health's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Flat

See what Global Health said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • Medanta has a significant bed addition pipeline expected to add approximately 3,450 beds over the next few years, nearly doubling network capacity to over 7,600 beds.
  • Planned capital expenditure is over INR 6,000 crores over the next 4 to 5 years, covering upcoming hospitals, capacity expansion at existing facilities, and supporting infrastructure.
  • New greenfield hospitals include a 500-bed multi-specialty hospital in Ghaziabad, among 6 new greenfield hospitals in the expansion pipeline.
  • Construction progress: South Delhi (GK) progressing well; Mumbai and Guwahati have approvals and active construction; Varanasi drawings submitted for approval.

2 more points from Global Health's call on capex

Create a free account to keep reading this call

Full Q2 FY27 analysis

FundraisingQ2 FY27 call

See what Global Health said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

  • Expansion pipeline includes 6 new greenfield hospitals aimed at doubling bed capacity over time.
  • Ongoing projects: South Delhi (GK), Mumbai, Guwahati, Varanasi, Pitampura (delayed due to revised approvals), and a recently acquired 2.61-acre land parcel in Ghaziabad for a 500-bed multi-specialty hospital.
  • Construction has started or is progressing on most sites, with some temporary slowdowns (e.g., monsoon in Guwahati, pollution norms in South Delhi).

2 more points from Global Health's call on the order book

Create a free account to keep reading this call

Full Q2 FY27 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Services
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Aster DM QualityGood growth
    3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Healthcare Services companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹867 Cr—
240%+Flat₹574 Cr21.8
3Aster DM Quality20–40%Up 2%+₹65,342 Cr124.7
420–40%Up 2%+₹14,999 Cr35.2
520–40%Up 2%+₹1,579 Cr15.6
620–40%Up 2%+₹587 Cr19.7

Sign up free to see every company in the sector ranking and track Global Health.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services ranking

Global Health announcements

All announcements →

Financials of Global Health

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Global Health

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +33.05%33.04%33.04%33.04%33.03%33.03%33.01%33.01%33.01%33.01%33.00%33.00%
FIIs +11.36%12.10%12.94%12.21%12.48%11.76%11.54%11.41%10.54%10.15%9.46%9.92%
DIIs +11.15%10.25%10.57%11.11%10.51%11.93%12.20%12.97%13.99%14.76%16.89%17.01%
Public +44.45%44.60%43.44%43.64%43.98%43.28%43.19%42.56%42.41%42.01%40.55%39.96%
Others +0.00%0.00%0.00%0.00%0.00%0.00%0.06%0.06%0.06%0.08%0.09%0.12%
No. of Shareholders1,24,7751,66,2531,55,3071,49,7221,48,6331,54,6881,56,3721,55,8061,51,2411,47,3901,40,5311,35,371

Financials of Global Health

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +8448368098619579439311,0311,0991,1211,1591,3041,469
YoY Sales growth+24%+20%+14%+10%+13%+13%+15%+20%+15%+19%+24%+26%+34%
Expenses +6316206296757287067077848689049151,0171,099
Operating Profit213216179186228238225247231217244287370
OPM %25%26%22%22%24%25%24%24%21%19%21%22%25%
Other Income +211827221816-272036-15372224
Interest20181818161615141722272728
Depreciation43444547494849455061676971
Profit before tax171172143144181189133208200120187213295
Tax %27%28%11%26%28%24%24%24%21%21%24%26%26%
Net Profit +12512412710613114310115915895142157219
EPS in Rs4.664.614.743.964.875.323.785.925.893.545.365.908.21

Financials of Global Health

Profit & Loss

Annual income statement trend

Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +1,3821,3431,4561,5001,4472,1672,7103,2753,6924,4105,053
Sales growth+8%+3%-4%+50%+25%+21%+13%+19%+26%
Expenses +1,0811,2181,2831,3091,2501,7092,0732,4662,8063,4803,935
Operating Profit3011251721921974586378098869301,118
OPM %22%9%12%13%14%21%24%25%24%21%22%
Other Income +4549504431394975299868
Interest14283857738686847490103
Depreciation7086102115123130150173194223267
Profit before tax26260836432281449627647715815
Tax %35%45%38%43%11%30%27%24%26%23%
Net Profit +17033513629196326478481554613
EPS in Rs7.021.362.091.471.167.7512.1617.8117.9220.7023.01
Dividend Payout %0%0%0%0%0%0%0%0%0%2%

Financials of Global Health

Balance Sheet

Capital structure and asset base

Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital4848494950515454545454
Reserves9761,1361,2461,3001,3331,5652,3752,8523,3333,9084,270
Borrowings +1654567879299311,1091,1228027181,1901,353
Other Liabilities +295343347388380421547572662753930
Total Liabilities1,4851,9842,4302,6662,6943,1464,0974,2804,7665,9056,606
Fixed Assets +9141,0941,1941,7031,6161,7762,0502,2362,5143,7953,957
CWIP12317666382464439327388533132207
Investments00000000333
Other Assets +5595735705816159301,7201,6561,7161,9752,440
Total Assets1,4851,9842,4302,6662,6943,1464,0974,2804,7665,9056,606

Financials of Global Health

Cash Flows

Operating, investing and financing cash movement

Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +22863166175242311645612624714
Cash from Investing Activity +-241-69-249-87-239-421-342-441-721-1,089
Cash from Financing Activity +-7997-1-81160346-514-97272
Net Cash Flow-2031487-7850648-343-194-103
Free Cash Flow71-81-133-1310038409335110-123
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit108%93%135%121%131%89%118%98%89%90%

Financials of Global Health

Ratios

Working capital efficiency and return ratios

Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days20414136343026242934
Inventory Days28262643423635322829
Days Payable9212414214713890114908189
Cash Conversion Cycle-45-56-75-67-62-24-52-34-24-26
Working Capital Days-23-33-18-31-48-20-37-32-21-7
ROCE %6%6%5%15%17%20%20%17%

Guidance history

How Global Health's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →20–40%FlatPlanned——
Q1 FY27 call →20–40%FlatPlannedPlannedRising
Q4 FY26 call →20–40%FlatPlanned—Rising
Q3 FY26 call →10–20%FlatPlanned—Rising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

66out of 100

Momentum score · price trend

66 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

PeriodShare price changeBetter than … of 1,928 stocks
Last 12 months+14.0%67%
Last 6 months+15.2%71%
Last 3 months−3.3%55%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,928 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Global Health: 0.4 × 67 + 0.4 × 71 + 0.2 × 55 = 66.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 9 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Others in Healthcare Services this season

  • Nidan Laboratories & Healthcare (Q2 FY27)

    Operating Margin: Not explicitly stated as a percentage; however, total income from operations is Rs 1,201.76 lakhs, so approximate operating margin = (EBITDA…

  • Suven Life Sciences (Q2 FY27)

    91.92 lakhs for the quarter ended September 30, 2025, indicating a revenue increase of approximately 30.3%. Key results statement takeaways from Suven Life Scie

  • Aster DM Quality (Q2 FY27)

    Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10). Key investor presentation takeaways from Aster DM Quality Care Ltd's Q2

  • Fortis Healthcare (Q2 FY27)

    Patient volume in diagnostics grew 5.8% YoY in Q2 and 9.9% quarter-on-quarter, with test volume growth at 7.2% YoY. Key concall takeaways from Fortis…